Dissociation of activated protein C functions by elimination of protein S cofactor enhancement

Shona Harmon1, Roger J S Preston, Fionnuala Ni Ainle

  • 1Haemostasis Research Group, Institute of Molecular Medicine, St James's Hospital, Trinity College, Dublin 8, Ireland.

Insights

Activated protein C (APC) is crucial for blood clotting and cell protection. Researchers found a specific mutation (L38D) that separates APC's anticoagulant and cell-protective functions, offering potential therapeutic benefits.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Hematology

Background:

  • Activated protein C (APC) has dual roles: anticoagulation by inactivating factors Va and VIIIa, and cytoprotection via PAR-1 signaling.
  • Protein S is a key cofactor for APC's anticoagulant function but its role in cytoprotective signaling is unknown.

Purpose of the Study:

  • To investigate the role of the APC Gla domain in protein S binding and function.
  • To characterize the impact of specific mutations on APC's anticoagulant and cytoprotective activities.

Main Methods:

  • Site-directed mutagenesis was used to create APC variants with amino acid substitutions in the Gla domain.
  • Assays were performed using purified proteins and plasma to measure Factor Va proteolysis and PAR-1 signaling.

Main Results:

  • Mutations D35T, D36A, and A39V showed mild impairment of protein S-dependent anticoagulant activity but normal cytoprotective activity.
  • The L38D mutation completely abolished protein S cofactor function, resulting in minimal anticoagulant activity.
  • APC-L38D retained normal interaction with the endothelial cell protein C receptor and PAR-1 signaling.

Conclusions:

  • Eliminating protein S cofactor enhancement of APC's anticoagulant function effectively separates its dual roles.
  • This separation offers a novel strategy for developing therapeutic applications of APC.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...